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Abstract
Background
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is often a life-threatening
arrhythmia disorder with variable penetrance and expressivity. Little is known about the inci-
dence or outcomes of CPVT patients with�2 variants.
Methods
The phenotypes, genotypes and outcomes of patients in the Pediatric and Congenital
Electrophysiology Society CPVT Registry with�2 variants in genes linked to CPVT were
ascertained. The American College of Medical Genetics & Genomics (ACMG) criteria and
structural mapping were used to predict the pathogenicity of variants (3D model of pig RyR2
in open-state).
Results
Among 237 CPVT subjects, 193 (81%) had genetic testing. Fifteen patients (8%) with a
median age of 9 years (IQR 5–12) had�2 variants. Sudden cardiac arrest occurred in 11
children (73%), although none died during a median follow-up of 4.3 years (IQR 2.5–6.1).
Thirteen patients (80%) had at least two RYR2 variants, while the remaining two patients
had RYR2 variants plus variants in other CPVT-linked genes. Among all variants identified,
re-classification of the commercial laboratory interpretation using ACMG criteria led to the
upgrade from variant of unknown significance (VUS) to pathogenic/likely pathogenic (P/LP)
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for 5 variants, and downgrade from P/LP to VUS for 6 variants. For RYR2 variants, 3D map-
ping using the RyR2 model suggested that 2 VUS by ACMG criteria were P/LP, while 2 vari-
ants were downgraded to likely benign.
Conclusions
This severely affected cohort demonstrates that a minority of CPVT cases are related to�2
variants, which may have implications on family-based genetic counselling. While multi-vari-
ant CPVT patients were at high-risk for sudden cardiac arrest, there are insufficient data to
conclude that this genetic phenomenon has prognostic implications at present. Further
research is needed to determine the significance and generalizability of this observation.
This study also shows that a rigorous approach to variant re-classification using the ACMG
criteria and 3D mapping is important in reaching an accurate diagnosis, especially in the
multi-variant population.
Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmia
syndrome characterized by ventricular tachycardia (VT) provoked by adrenergic stress. [1]
The condition is caused by excessive calcium leak from the sarcoplasmic reticulum, leading to
delayed after-depolarizations and arrhythmias. [1] Most cases are attributed to mutations in
RYR2-coded ryanodine receptor (RyR2) or CASQ2-coded calsequestrin-2 [1]. Although less
recognized, SCN5A, TRDN, and CALM1-3 have also been implicated in catecholamine sensi-
tive polymorphic VT. [2–7]
To date, genotype-based risk predictors have not been clinically useful. In other inherited
arrhythmic conditions, like long QT syndrome (LQTS) and hypertrophic and arrhythmogenic
cardiomyopathies, patients with double and compound mutations fare especially poorly. [8–
12] We used the Pediatric and Congenital Electrophysiology Society (PACES) Registry [13, 14]
to characterize CPVT patients with�2 variants. To systematically assess the likelihood of path-
ogenicity, variants were mapped on to the 3D structure of RyR2, which provides mechanistic
insights into their function and enhances the analysis compared to sequence-based scoring
algorithms alone.
Material and methods
This is a retrospective study derived from the PACES CPVT Registry, which is an international
multicenter registry of children (�19 years) and their first-degree relatives with a diagnosis of
CPVT made by consensus criteria. [1] Clinical, genotypic and outcome data were previously
reported. [13, 14] Participating sites received ethical approval locally and the protocol adhered
to the 1975 Declaration of Helsinki. The coordinating center was responsible for data collec-
tion and analysis, and the protocol was approved by the UBC C&W Research Ethics Board.
The review board did not require individual patient consent as the study was a retrospective
chart review. All data were de-identified prior to entry and analysis. A stepwise bioinformatics
approach was implemented to classify variant pathogenicity, including structural mapping
using 3D model of pig RyR2 in open-state (Fig 1). Continuous data are presented as the
median (interquartile range). Detailed methods are available in the supporting supplemental
information (S1 File and S2 File).
Multi-variant CPVT
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Results
Population
Of 237 patients entered in the PACES CPVT Registry, 193 (81%) underwent genetic testing.
There were 15 patients (8%) from 12 families with�2 variants. Table 1 summarizes the geno-
types and phenotypes of these multi-variant carriers. The median age at presentation was 9
years (IQR 5–12) and 9 (60%) were female. Thirteen children (87%) had�2 RYR2 variants,
one had CASQ2 and RYR2 variants, and one had RYR2 and SCN5A variants (Table 1, Table 2
and S2 File). There were 12 children (80%) who were probands. Inheritance could not be
established in 6 children (40%) owing to a lack of parental genetic data. A family history of
Fig 1. Domain architecture of the cardiac RyR2. Domains are coloured according to the linear sequence scheme shown above the ribbon diagram. Structure obtained
from PDB: 5GOA. [15] The ribbon diagram shows a RyR2 dimer from the side. Red circles represent large alpha solenoid regions which are unstructured in the cryo-
electron micrograph (CryoEM) structure. All variants discussed in the manuscript are shown in sphere representations. Red squares highlight location of the most likely
damaging variants (expanded in Fig 2). Domains are named according to nomenclature used by des Georges, et al., 2016. A (dark orange), B (green), and C (light blue)
domains: form part of the N-terminal domain (NTD); NSol (dark blue): alpha-solenoid region near the NTD; SPRY1 (light orange), SPRY2 (dark green), and SPRY3
(dark grey): three domains named after splA kinase and RyRs where they were first identified; Sol2 (light grey): second alpha-solenoid region centrally located on RyR2;
Rep12 (yellow) and Rep23 (brown): four repeats (~100 aa each) in two tandem arrangements, Repeats 1 and 2 located between SPRY 1 and SPRY2, and Repeats 3 and 4
located within Sol2; CSol3 (magenta): third alpha-solenoid region located near the C-terminal; EFs (red): pair of EF hand-like motifs located within CSol3 region; TaF
(light green): thumb and forefingers domain; DR1/2/3 (white): evolutionary divergent regions of RyR isoforms (not shown in the ribbon diagrams); pVSD (gold): pseudo
voltage-sensing domain; PFD (wheat): pore-forming domain; CTD (pink): C-terminal domain.
https://doi.org/10.1371/journal.pone.0205925.g001
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Table 2. Clinical and molecular data supporting variant classification.
Subject
(s)
Variants Reported pathogenicity
from commercial testing
lab
ExAC browser
allele frequency
Pathogenicity re-
classification based on
ACMG Criteria
Predicted structural impact based on RyR2 model
1, 2 RYR2-p.R417L
(Fig 2A)
P/LP Absent Likely Pathogenic R417 is located near the anion-binding site in domain C, at
domains A-C and B-C interfaces. The inter-domain area is
dominated by hydrophilic and charged residues. The R417L
variant would introduce a shorter, hydrophobic side chain in
place of a bulky, positively charged side chain, which may
alter the anion binding and cause domain-domain
rearrangements.
RYR2-p.F3496L VUS Absent Likely Pathogenic F3496 is located in an intrinsically disordered alpha-
solenoidal region of RyR2 (Sol2).
3 RYR2-p.R485Q
(Fig 2A)
VUS 0.00008645 Likely Pathogenic R485 is located inside an alpha helix of domain C, buried
within the helical bundle. The R485 side chain forms a salt
bridge with the E411, located in another helix facing
domains A and B. The R485Q variant would break this
interaction, destabilizing domain C, and affect the anion
binding site.
RYR2-p.S3938R P/LP Absent Likely Pathogenic S3938 is located in the CSol3 region of RyR2. S3938 is near
the pore, within the cytosolic side of the channel. Mutation
to bulkier, positively charged side chain may alter hydrogen
bonding pattern at this site and/or disrupt surrounding
alpha helices structure.
4, 5, 6 RYR2-p.I2075T
(Fig 2B)
P/LP Absent VUS I2075 is located within the Sol2 region, where it is buried
between two helices. The Ile residue is surrounded by
hydrophobic residues. The variant is close to an interface
with Csol3 region, and thus the variant may impact this
inter-domain interaction.
RYR2-p.
K4594R
(Fig 2C)
VUS Absent Likely Pathogenic K4594 is located at the cytosolic edge of the pseudo voltage-
sensing domain (pVSD), next to the thumb and forefingers
(TaF) domain. These domains are implicated in the binding
of activating ligands and channel opening. Although the
K4594R substitution is conservative, the guanidinium group
of Arg allows for a larger number of interactions or may
facilitate a stronger interaction with nearby E4200. The ATP/
Caffeine binding sites located nearby, thus any small
perturbation in this area is likely to alter channel gating.
7 RYR2-p.
R2028H
P/LP Absent VUS R2028 is found in Sol2 region of RyR2, pointing toward the
solvent. The variant is unlikely to have a major impact on the
function, but may influence binding to an unknown
auxiliary protein.
RYR2-p.
Y4721C
(Fig 2D)
P/LP Absent Likely Pathogenic This residue is located within the transmembrane region of
pVSD. This region plays an important role in allosteric
gating of the channel and the Tyr is surrounded by other
hydrophobic residues. Mutation to cysteine is likely to
perturb channel gating and domain packing.
8 RYR2-p.
T1107M
(Fig 3A)
VUS Absent Pathogenic T1107 is located within the SPRY2 domain, where it is
buried and surrounded by hydrophobic residues. The variant
would form steric clashes with W1156 and cause
destabilization of the domain, as shown in a crystallographic
study of this mutant[19]. Functional experiments have
shown it affects Ca2+ release properties (see suppl. table 1).
CASQ2-c.IVS5
+1G>C
P/LP Absent VUS Not performed
9 RYR2-p.
R2474K
(Fig 3B)
P/LP Absent Likely pathogenic R2474 is located in the Sol2 region of RyR2, near two other
mutations. Region is poorly resolved in CryoEM structures.
The variant is subtle and structural predicted suggests a
minimal impact. It is currently unknown whether any
auxiliary protein binds to this region.
(Continued)
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Table 2. (Continued)
Subject
(s)
Variants Reported pathogenicity
from commercial testing
lab
ExAC browser
allele frequency
Pathogenicity re-
classification based on
ACMG Criteria
Predicted structural impact based on RyR2 model
RYR2-p.
A1136V
VUS 0.007063 Likely pathogenic A1136 is located within the SPRY2 domain. The equivalent
residue in both RyR1 and RyR3 is a valine, therefore the
mutation is unlikely to have significant negative impact on
the overall structure of RyR.
10 RYR2-p.L4188P
(Fig 3C)
VUS Absent VUS L4188 is located within a helix as part of the TaF domain that
clamps the C-terminal extension of the RyR. This interaction
is critical for channel gating. The substitution to Pro may
promotes helix breaking, and potentially perturb channel
gating.
RYR2-p.G1886S VUS 0.04385 VUS G1886 is located in a flexible unstructured loop as part of
Sol2 region. Though the substitution alone is unlikely to
have an impact on channel gating, it may have indirect
effects such as creation of a new phosphorylation site.
11 RYR2-p.S2246L
(Fig 3D)
P/LP Absent Pathogenic S2246 is located within the Sol2 region, where the side chain
is tightly packed next to an alpha helix. Mutation to a longer
side chain likely results in steric clashes, and will impact
helix packing in this region.
RYR2-p.G1886S VUS 0.01540 VUS G1886 is located in a flexible unstructured loop as part of
Sol2 region. Though the substitution alone is unlikely to
have an impact on channel gating, it may have indirect
effects such as creation of a new phosphorylation site or alter
bidding to auxiliary protein(s).
12 RYR2-p.
H2464D
P/LP Absent Pathogenic H2464 is located within a poorly resolved Sol2 region of
RyR2 structure. The variant may impact binding of an
unknown auxiliary protein to this region.
RYR2-p.
G1885E
VUS 0.04385 VUS G1885 is located in a flexible unstructured loop of RyR2, and
thus cannot be mapped onto the existing structure.
13 RYR2-p.
R2401H
(Fig 3B)
P/LP Absent Likely Pathogenic R2401 is located within the Sol2 region, near two other
CPVT associated mutations. Substitution to His may have an
impact on helix stability.
DSG-p.V288I VUS Absent VUS Not performed
14 RYR2-p.G4772S P/LP Absent VUS G4772 is located in the pore forming domain (PFD), as part
of the outer helix. Substitution to less flexible Ser may affect
helical packing within the membrane and cause subtle
domain rearrangements.
CACNA1c-p.
T1870M
VUS Absent VUS Not performed
RYR2-c.3599-
9delT
VUS Absent VUS Not performed
RYR2-c.14091-
11dupT
VUS Absent VUS Not performed
CACNA1C-
c.5680+11C>T
VUS Absent VUS Not performed
TMEM43-c.512
+19G>T
VUS Absent VUS Not performed
PKP2-c.2300-
4G>C
VUS 0.00008079 VUS Not performed
DSP-p.R1458G P/LP 0.001737 VUS Not performed
15 RYR2-p.A2317E
(Fig 3B)
P/LP Absent VUS A2317 is in an alpha solenoid region, near two other CPVT
associated mutations. Mutation to the larger Glu residue
likely forms steric clashes with nearby residues, and this is
likely to affect packing and stability of the region.
(Continued)
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suspected/confirmed CPVT was reported in 10 patients (67%). VT and/or sudden cardiac
arrest (SCA) occurred in 13 of 15 cases (87%). The exceptions were subject #6 who was asymp-
tomatic and subject #12 who had exertional syncope and seizures. Pedigrees for patients from
select families are available in the supporting information (S3 File).
Therapies & outcomes
Anti-arrhythmic therapy was instituted in 13 of 15 patients (87%). One patient received no
treatment (subject #2), and in one patient, only an implantable cardioverter-defibrillator
(ICD) was used (subject #6). A beta-blocker was prescribed in all treated patients. Therapeutic
escalation with flecainide and left cardiac sympathectomy was necessary in subject #8 due to
arrhythmias on beta-blockers. He continued to have events despite these ancillary treatments.
Subject #12 also received flecainide for refractory arrhythmias and valproate for seizures, while
subject #15 eventually had a left cardiac sympathectomy. An ICD was implanted in 10 of 15
patients (67%), 9 of which were for secondary prevention after SCA. Treatment failure
occurred in 4 of 13 subjects (31%) on medication. No patients died during a median follow-up
of 4.3 years (IQR 2.5–6.1).
Genetic analysis
Based on American College of Medical Genetics and Genomics (ACMG) criteria, 13 of 29 var-
iants (45%) were defined as pathogenic/likely pathogenic (P/LP) after a review of the literature
and population allele frequencies in the Exome Aggregation Consortium (ExAC) browser
[16]. A remaining 16 (65%) were variants of unknown significance (VUS) by ACMG criteria.
Table 2 and the supplemental (S2 File) summarize the variants in this population and the clini-
cal and molecular data to support variant pathogenicity using our stepwise approach to classi-
fication. We then undertook a detailed analysis of RYR2 variants using the 3D structure of pig
and mouse RyR2 [15, 17] (Figs 1 & 2) based on several rationales. Firstly, predicting the patho-
genicity of variants on sequence alone does not consider the chemical environment of the
affected residues. Substitutions of amino acid residues involved in protein folding, domain-
domain interactions, and interactions with auxiliary ligands are much more likely to affect
function than residues simply pointing to solvent. This type of information is not available
from sequence-based algorithms like the Polyphen score. Secondly, knowledge of the 3D envi-
ronment can give possible clues on the disease mechanism. [18] Of 21 RYR2 variants identified
in this study, 12 could be mapped on the open-state structure of RyR2 (Figs 2 and 3), and 11
would likely have a damaging effect on channel function (p.R417L, p.R485Q, p.S3938R, p.
K4594R, p.Y4721C, p.S2246L, p.H2464D, p.R2401H, p.L4188P, p.A2317E and p.T1107M). Of
note, 2 of these were initially classified as VUS by ACMG criteria (p.L4188P and p.A2317E). In
contrast, one RYR2 pathogenic variant (p.A1136V) and one VUS (p.R2028H) by ACMG
Table 2. (Continued)
Subject
(s)
Variants Reported pathogenicity
from commercial testing
lab
ExAC browser
allele frequency
Pathogenicity re-
classification based on
ACMG Criteria
Predicted structural impact based on RyR2 model
SCN5A-p.
Q692K
P/LP 0.0002822 VUS Mutation site is on the 1–2 linker (DI-II loop) near the start
the VSD of the cardiac voltage-gated sodium channel
(NaV1.5). The region is important to gating function of the
channel and is in close proximity to the CaMKII binding
site. The mutation may also influence binding to other
auxiliary proteins.
https://doi.org/10.1371/journal.pone.0205925.t002
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standards appeared benign based on structural mapping and sequence conservation. The
model for each of these variants appear in Figs 2 & 3. The supplemental (S2 File) provides all
the original data for the classification of each variant.
Discussion
In this study, multi-variant CPVT occurred in 8% of the PACES CPVT Registry. Nearly three-
quarters of these children were SCA survivors and many had variants that were likely patho-
genic. While this cohort of multi-variant CPVT patients were severely affected, there are insuf-
ficient data to conclude whether this genetic phenomenon has prognostic implications. Even
in the absence of prognostic utility, multi-variant CPVT is relevant to decision-making around
cascade family screening. In total, there were 3 possible situations observed: (1) double variants
in cis, (2) compound heterozygous variants in trans, and (3) digenic heterozygous variants
Fig 2. Location of CPVT-associated variants on RyR2 structure. Enlarged view of the insets are presented to highlight location of the variants and nearby residues/
secondary structures. Domains are coloured according to the linear sequence scheme shown in Fig 1. All variants occur in highly conserved regions of all three RyR
isoforms. Unless specified, the structures are based on the 4.2 Å resolution CryoEM open-state structure of RyR2 from porcine heart[15], PDB: 5GOA. (A) RYR2-p.
R417L and RYR2-p.R485Q mutants are located centrally within RyR2 ABC domains, near the anion binding site. Residues involved in the formation of the Cl- pocket
are highlighted. R485 forms a salt bridge interaction with nearby E411 residue. (B) The RYR2-p.I2075T is located within a flexible linker, joining two alpha-helices
together in the Sol2 region. The Ile is surrounded by nearby hydrophobic residues. (C) The RYR2-p.K4594R variant is located in the pVSD domain, near the TaF
domain. Mutation to Arg, may potentially form a salt bridge with a nearby E4199 located on the TaF domain. In RyR1 open-state structure[20] the K4594 is located near
activating ligands such as caffeine and ATP, PDB: 5TAQ. (D) The RYR2-p.Y4721C variant is located within the transmembrane region of pVSD, and unsurprisingly the
Y4721 is surrounded by other hydrophobic residues. Y4721 is potentially forming a polar contact with carboxyl group D4745.
https://doi.org/10.1371/journal.pone.0205925.g002
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(different genes). As will be discussed, each scenario creates a unique set of diagnostics, cas-
cade screening and prognostic implications.
The cumulative gene dosage phenomenon is similarly rare for hypertrophic cardiomyopa-
thy, [9, 10] arrhythmogenic right ventricular cardiomyopathy, [11] and LQTS [8, 12], com-
pared to CPVT in the PACES Registry. Multi-variant CPVT children were usually severely
affected (73% with SCA). In comparison to the rest of the Registry population (38% with
SCA), the severity of multi-variant CPVT appeared greater, but these data are not sufficient to
imply that disease severity is directly influenced by the number of mutations. Statistical com-
parisons between single vs. multiple variant phenotypes were not undertaken due to the rela-
tively small population described here, and the historical uncertainty around the genetic
testing protocols/techniques which pre-dated enrollment in the registry. For example, early
on, commercial genetic testing companies were only testing select RYR2 exons and older
reports in the Registry were sometimes incomplete. Additionally, the second variant was
sometimes a VUS, and/or potentially benign based on our mapping and/or found in cis phase.
Fig 3. Location of CPVT-associated variants on RyR2 structure (continued). (A) RYR2-p.T1107M and p.A1136V mutations are located within the SPRY2 domain,
where they are buried and surrounded by hydrophobic residues. (B) The RYR2-p.R2474K, R2401H, and RYR2-A2317E mutants are clustered within the central alpha-
solenoid region of RyR2 (Sol2). The R2401 and R2474 potentially interacts with nearby D2397 and S2312 respectively. These mutations are in close proximity to the
CSol3 region and the unstructured region of Sol2. This region is intrinsically flexible and generally poorly resolved in the CryoEM map. (C) RYR2-p.L4188P mutation is
located in the TaF domain where it is surrounded by hydrophobic residues. (D) RYR2-p.S2246L mutation is located in the better resolved region of Sol2, where the side
chain is tightly packed against neighbouring alpha helix.
https://doi.org/10.1371/journal.pone.0205925.g003
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In such settings, CPVT may be driven by a single variant or the second variant could be a risk
modifier. An example is RYR2-p.G1886S, which occurred in 2 of our patients, and was also
seen in the general population. [16] A recent study has shown that this variant is a significant
risk factor for ventricular arrhythmias in heart failure patients [21], suggesting that it could be
a candidate risk modifier in CPVT. A parallel effect exists in the LQTS genes where common
variants underlie a susceptibility to drug-induced QT prolongation [22, 23] but do not cause
overt LQTS. For example, KCNE1-p.D85N is too common in the population to independently
cause LQTS, but significantly increases risk if a second LQTS mutation occurs. [24, 25] In our
cohort, subject #14 carried a CACNA1C VUS and a pathogenic RYR2 mutation (plus several
other RYR2 VUS), and had a classic CPVT phenotype (catecholamine triggered bidirectional
VT) with some QT prolongation. We hypothesize that a possible LQTS variant, plus multiple
variants linked to CPVT, may have collectively contributed to his severe overlap phenotype
(ie. digenic heterozygosity). Quite remarkably, another boy had two forms of CPVT (type-1
due to RYR2-p.T1107M and type-2 due to CASQ2-c.IVS5+1G>C). While CPVT type-2 alone
can be especially dangerous, the RYR2-p.T1107M variant also likely has a damaging role based
on the present data, and previous studies showing both a clinical and in vitro phenotype [19,
26]. The growing international CPVT registry and prospective data are needed to clarify the
risk and incidence of multi-variant CPVT.
The presence�2 variants creates other logistical problems. We could not differentiate
between cis and trans variants in some cases owing to the inconsistent screening of the parents.
Incomplete parental screening may be due to the clinicians’ uncertainty regarding the disease-
causing variant in the family, thus demonstrating another challenge in this circumstance. Vari-
ants in cis phase similarly confounds screening in hypertrophic cardiomyopathy. [27] In cis
phase, the CPVT phenotype would not necessarily be worse than any given single variant.
However, the presence of�2 cis variants is relevant, as it demonstrates the complexities
around family screening in the setting of CPVT. RYR2 variants in trans phase have a theoreti-
cal mechanism for increased severity. RyR2 is a large, homotetrameric protein made up of 4
subunits. Two variants in trans phase would mean that all 4 subunits making up the channel
would be mutated. In contrast, in the typical case of autosomal dominant CPVT, half of the
four subunits would be wildtype. Theoretically, this could account for a more severe phenotype
in compound multi-variant CPVT. Based on the present study, we propose that targeted
sequencing for both variants be performed in the clinical setting, and that relatives, especially
parents, need to be evaluated by an expert to clarify the role of each variant.
The unclear pathogenicity of RYR2 variants is a growing concern in CPVT. [28] We used a
standardized bioinformatics approach to variant interpretation to avoid overcalling pathoge-
nicity. After applying the ACMG criteria, we mapped variants on the open-state structure of
RyR2 to see if any other insights could be obtained. This technique relies on the 3D structure
derived from high resolution studies of the ryanodine receptor. A good example of this is the
N-terminal region of RyR2, which consists of three domains: domain A (residues 1–217) and
domain B (residues 218–409), and domain C (residues 410–543) (Fig 1). [29–31] A chloride
ion is coordinated by residues of all three domains and disruption of this binding site via dis-
ease-causing variants results in domain reorientations. [17, 29, 32] These observations suggest
that CPVT variants may destabilize domain interfaces or disrupt the folding of individual
domains, which would impair domain-domain interactions and cause adverse effects on channel
gating. [17, 20, 29, 31–34] Structural analyses supported downgrading p.A1136V and p.R2028H
to likely benign. RYR2-p.A1136 is located in a relatively non-conserved region within the SPRY2
domain, where its equivalent residue in both RyR1 and RyR3 is a valine, thus substitution to
valine is unlikely to alter the function of RyR2 significantly. Further, structural mapping showed
that valine substitution can be easily accommodated without the formation of steric clashes. The
Multi-variant CPVT
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p.R2028H mutation is located in a flexible region of RyR2, where the side chain is pointing
towards the solvent, and thus the mutation is unlikely to have a major impact on channel func-
tion. These are not functional assays, so the conclusions are predictive in nature.
This study is limited by its retrospective design. Genetic testing spanned nearly 15 years,
and not all commercial testing companies provided technical details as would be required
in the contemporary era. Results for family members were sometimes not available (often if
followed by a non-participating center). Early commercial sequencing methods could not dif-
ferentiate between two variants in the cis vs. trans position of RYR2 (unpublished communica-
tion). Limitations also exist in the structural analysis of variants, whereby some portions of
RyR2 structure are poorly defined in the CryoEM structure. The best-defined regions are
domains whose structures have been determined via X-ray crystallography (N-terminal
domains, SPRY1/2, Rep12, and Rep34 domains), followed by the C-terminal and transmem-
brane regions, for which the resolution of CryoEM studies is the highest [18]. As such, direct
analysis of variants in the N-terminal and C-terminal hotspots is the most reliable. For most
other sections, direct analysis of hydrogen bonds and ionic interactions of the variants is not
yet possible, however their general location in the 3D structure can be determined at the cur-
rent resolution for RyR2. A detailed supplemental disclosing all the supporting data is pro-
vided to facilitate re-classification by future researchers as the field advances.
Conclusions
More than one variant may underlie a minority of CPVT cases. This poses challenges with
respect to diagnosis and family counselling. While multi-variant CPVT patients were usually
severely affected, further research is needed to determine the significance and generalizability
of this observation. We demonstrate that a rigorous approach to variant re-classification using
the ACMG criteria and 3D mapping is important in reaching an accurate diagnosis, especially
in the multiple variant population.
Supporting information
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